Successive mRNA vaccinations enhanced cross-variant antibody evolution in immunosuppressed patients, though responses varied by treatment type, according to a new study.
Researchers found no significant reduction in hospitalizations or mortality among highly vaccinated older adults with increased access to nirmatrelvir-ritonavir.